Mr. Connolly currently serves as CEO of Tivorsan Pharmaceuticals and is on the Board of Directors of Aeras and Vaxess Technologies. Mr. Connolly is also an advisor to the Crossover Healthcare Fund. Prior, he was President and CEO of Aeras, a nonprofit biotech company developing vaccines for tuberculosis and other neglected diseases. Before that, he spent more than 23 years at Wyeth (now part of Pfizer) where he served in a series of senior roles including Executive Vice President and General Manager of Wyeth Vaccines and President of Wyeth Canada. Mr. Connolly holds a B.S. in Business Administration from Washington University. Mr. Connolly currently serves as CEO of Tivorsan Pharmaceuticals and is on the Board of Directors of Aeras and Vaxess Technologies. Mr. Connolly is also an advisor to the Crossover Healthcare Fund. Prior, he was President and CEO of Aeras, a nonprofit biotech company developing vaccines for tuberculosis and other neglected diseases. Before that, he spent more than 23 years at Wyeth (now part of Pfizer) where he served in a series of senior roles including Executive Vice President and General Manager of Wyeth Vaccines and President of Wyeth Canada. Mr. Connolly holds a B.S. in Business Administration from Washington University.

Management